FPR1/NOX2 Agonist Program (e.g., RE-04-001)

About Pronoxis

ProNoxis is a preclinical-stage biotech company pioneering a novel therapeutic approach by developing small-molecule agonists of the FPR1/NOX2 pathway to harness the body's natural immune mechanisms for resolving inflammation and fighting infections. The company's lead assets are highly potent, selective FPR1 agonists with proof-of-concept data in relevant disease models. Following a recent corporate restructuring, its core preclinical project and IP were transferred to spin-off Inicure AB in 2024, with ProNoxis continuing to support the program's advancement through grant funding and partnerships.

Therapeutic Areas